Tango Therapeutics, Inc. filings document a clinical-stage precision oncology business and its Nasdaq-listed common stock. Current reports disclose operating and financial results, business highlights for vopimetostat and related development programs, material agreements, capital-raising arrangements such as at-the-market common stock sales, and updates to governance and executive leadership.
Proxy and compensation disclosures cover board matters, executive pay, pay-versus-performance data, equity awards, and shareholder voting matters. The company’s filings also address officer appointments and departures, separation and employment agreements, compensatory arrangements, capital structure, risk factors, and other material events affecting its biotechnology operations.
Tango Therapeutics, Inc. (TNGX) filed a Form 144 reporting a proposed sale of 302,194 common shares through BTIG, LLC with an aggregate market value of $2,085,138.60, intended to be sold on 08/22/2025 on the NASDAQ GM. The filer acquired these shares on 03/23/2017 as a pre-IPO investment from Tango Therapeutics, Inc., and payment for that acquisition was by wire. The filing also discloses a related sale in the past three months: Third Rock Ventures IV, L.P. sold 1,100,000 common shares on 08/19/2025 for gross proceeds of $7,712,760.00. The notice includes the filer’s standard representation that no undisclosed material adverse information is known.
Third Rock Ventures entities reported a sale of Tango Therapeutics (TNGX) common stock on 08/19/2025. The filing states 1,100,000 shares were sold at a weighted-average price of $7.0116 per share (prices ranged $7.00–$7.12). After the sale, Third Rock Ventures IV, L.P. is reported to beneficially own 15,759,075 shares, held indirectly through its GP entities. The report is filed by multiple related reporting persons and includes the standard disclaimers that the GP entities disclaim beneficial ownership except for any pecuniary interest.
Tango Therapeutics, Inc. (TNGX) filing a Form 144 notifies of a proposed sale of 1,100,000 common shares — an aggregate market value of $7,656,000.00 — to be executed through BTIG, LLC on the NASDAQ GM with an approximate sale date of 08/19/2025. The shares were acquired as a Pre-IPO investment from Tango Therapeutics Inc. on 03/23/2017, paid via wire. The filer reports no securities sold in the past three months and certifies no undisclosed material adverse information. The notice follows Rule 144 disclosure requirements for proposed insider or affiliate sales.
Tango Therapeutics disclosed that Woodline Partners LP, acting as investment adviser to Woodline Master Fund LP, beneficially owns 6,029,906 shares of the company's common stock. That holding represents approximately 5.6% of the class based on an aggregate of 108,394,190 shares outstanding as reported in the company's quarterly report. The reporting party states it has sole voting and sole dispositive power over those shares.
The filing notes the shares are held in the ordinary course of business and were not acquired for the purpose of changing or influencing control of the issuer. The report identifies Woodline Partners as a Delaware limited partnership and names the Woodline Fund as the direct holder of the reported shares.
Farallon-affiliated funds and related individuals filed an amended Schedule 13G reporting material passive holdings of Tango Therapeutics common stock. Farallon Partners, L.L.C. is shown as beneficial owner of 8,798,334 shares (8.1%) and the Farallon Individual Reporting Persons are shown with a collective 9,157,000 shares (8.4%). Several underlying Farallon funds report individual holdings, including Farallon Capital Offshore Investors II with 3,754,671 shares (3.5%) and Farallon Capital Institutional Partners with 2,023,027 shares (1.9%).
The filing states the shares are held directly by the named funds and that the general partner entities and listed individuals could be deemed beneficial owners while disavowing beneficial ownership of those shares. The Schedule is a passive disclosure of ownership and includes a certification that the securities were not acquired to effect a change of control.
Adage Capital Management, L.P., together with Robert Atchinson and Phillip Gross, reports beneficial ownership of 5,905,349 shares of Tango Therapeutics common stock, equal to 5.45% of the company’s outstanding shares based on an 108,394,190 share count used in the filing. The reported position shows shared voting and dispositive power of 5,905,349 shares and no sole voting or dispositive power.
The filing is submitted on Schedule 13G and states the securities are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.